A new algorithm Precision OncoPanels (PrOPs) identifies short individualized actionable panels that can guide cancer

Shrisruti Sriraman1, Debajyoti Das2, Nagasuma Chandra1,2,3

  • 1IISc Mathematics Initiative, Indian Institute of Science, Bangalore 560012, India.

PubMed

Insights

Precision oncology uses next-generation sequencing (NGS) for tailored cancer treatment. A new algorithm, PrOPs, identifies actionable gene panels for all patients, improving personalized cancer care.

Area of Science:

  • Genomics
  • Bioinformatics
  • Computational Biology

Background:

  • Precision oncology leverages next-generation sequencing (NGS) for personalized cancer diagnosis and treatment.
  • Current NGS approaches benefit limited patient groups with common mutations, necessitating broader applicability.
  • A gap exists in identifying actionable gene panels for all cancer patients.

Purpose of the Study:

  • To develop a novel algorithm, PrOPs (Precision Onco Panels), for identifying short, actionable driver gene panels.
  • To integrate multi-omics data (genomics, transcriptomics, protein-protein interactions) for enhanced driver gene identification.
  • To address the need for comprehensive genomic analysis in precision oncology.

Main Methods:

  • Developed the PrOPs algorithm integrating genomics, transcriptomics, and protein-protein interaction networks.
  • Constructed and analyzed precision networks to identify patient-specific cancer drivers.
  • Validated the algorithm on 2180 patients across six cancer types from The Cancer Genome Atlas (TCGA).

Main Results:

  • PrOPs successfully identified patient-specific cancer driver genes.
  • The algorithm outperformed existing network-based methods in personalized driver identification.
  • Clinically relevant actionable panels were identified in 93% of tested patient cases.
  • PrOPs captured rare and patient-specific cancer drivers effectively.

Conclusions:

  • The PrOPs algorithm enhances precision oncology by identifying actionable gene panels for a wider patient population.
  • Demonstrated generalizability across six cancer types highlights its clinical utility.
  • PrOPs represents a significant advancement in personalized cancer treatment strategies.